Epigenome editing

Epigenome editing or epigenome engineering is a type of genetic engineering in which the epigenome is modified at specific sites using engineered molecules targeted to those sites (as opposed to whole-genome modifications). Whereas gene editing involves changing the actual DNA sequence itself, epigenetic editing involves modifying and presenting DNA sequences to proteins and other DNA binding factors that influence DNA function. By "editing” epigenomic features in this manner, researchers can determine the exact biological role of an epigenetic modification at the site in question.

The engineered proteins used for epigenome editing are composed of a DNA binding domain that target specific sequences and an effector domain that modifies epigenomic features. Currently, three major groups of DNA binding proteins have been predominantly used for epigenome editing: Zinc finger proteins, Transcription Activator-Like Effectors (TALEs) and nuclease deficient Cas9 fusions (CRISPR).

General concept

Comparing genome-wide epigenetic maps with gene expression has allowed researchers to assign either activating or repressing roles to specific modifications. The importance of DNA sequence in regulating the epigenome has been demonstrated by using DNA motifs to predict epigenomic modification.^[1] Further insights into mechanisms behind epigenetics have come from in vitro biochemical and structural analyses. Using model organisms, researchers have been able to describe the role of many chromatin factors through knockout studies. However knocking out an entire chromatin modifier has massive effects on the entire genome, which may not be an accurate representation of its function in a specific context. As one example of this, DNA methylation occurs at repeat regions, promoters, enhancers, and gene bodies. Although DNA methylation at gene promoters typically correlates with gene repression, methylation at gene bodies is correlated with gene activation, and DNA methylation may also play a role in gene splicing.^[2] The ability to directly target and edit individual methylation sites is critical to determining the exact function of DNA methylation at a specific site. Epigenome editing is a powerful tool that allows this type of analysis. For site-specific DNA methylation editing as well as for histone editing, genome editing systems have been adapted into epigene editing systems. In short, genome homing proteins with engineered or naturally occurring nuclease functions for gene editing, can be mutated and adapted into purely delivery systems. An epigenetic modifying enzyme or domain can be fused to the homing protein and local epigenetic modifications can be altered upon protein recruitment. Exceptionally for DNA methylation, the homing domain itself can be enough to interfere with normal epigenetic processes to lead to targeted epigenetic editing.^[3]

Targeting proteins

TALE

The Transcription Activator-Like Effector (TALE) protein recognizes specific DNA sequences based on the composition of its DNA binding domain.^[4] This allows the researcher to construct different TALE proteins to recognize a target DNA sequence by editing the TALE's primary protein structure. The binding specificity of this protein is then typically confirmed using Chromatin Immunoprecipitation (ChIP) and Sanger sequencing of the resulting DNA fragment.^[5]^[6]^[7] This confirmation is still required on all TALE sequence recognition research.^[8] When used for epigenome editing, these DNA binding proteins are attached to an effector protein. Effector proteins that have been used for this purpose include Ten-eleven translocation methylcytosine dioxygenase 1 (TET1),^[6] Lysine (K)-specific demethylase 1A (LSD1)^[7] and Calcium and integrin binding protein 1 (CIB1).^[5]

Zinc finger proteins

The use of zinc finger-fusion proteins to recognize sites for epigenome editing has been explored as well. Maeder et al. has constructed a ZF-TET1 protein for use in DNA demethylation.^[6] These zinc finger proteins work similarly to TALE proteins in that they are able to bind to sequence specific sites in on the DNA based on their protein structure which can be modified. Chen et al. have successfully used a zinc finger DNA binding domain coupled with the TET1 protein to induce demethylation of several previously silenced genes.^[9] Kungulovski and Jeltsch successfully used ZFP-guided deposition of DNA methylation gene to cause gene silencing but the DNA methylation and silencing were lost when the trigger signal stopped. The authors suggest for stable epigenetic changes, there must be either multiple depositions of DNA methylation of related epigenetic marks, or long-lasting trigger stimuli.^[10] ZFP epigenetic editing has shown potential to treat various neurodegenerative diseases.^[11]

CRISPR-Cas

The Clustered Regulatory Interspaced Short Palindromic Repeat (CRISPR)-Cas system functions as a DNA site-specific nuclease.^[12] In the well-studied type II CRISPR system, the Cas9 nuclease associates with a chimera composed of tracrRNA and crRNA. This chimera is frequently referred to as a guide RNA (gRNA). When the Cas9 protein associates with a DNA region-specific gRNA, the Cas9 cleaves DNA at targeted DNA loci. However, when the D10A and H840A point mutations are introduced, a catalytically-dead Cas9 (dCas9) is generated that can bind DNA but will not cleave.^[13] The dCas9 system has been utilized for targeted epigenetic reprogramming in order to introduce site-specific DNA methylation. By fusing the DNMT3a catalytic domain with the dCas9 protein, dCas9-DNMT3a is capable of achieving targeted DNA methylation of a targeted region as specified by the present guide RNA.^[14] Similarly, dCas9 has been fused with the catalytic core of the human acetyltransferase p300. dCas9-p300 successfully catalyzes targeted acetylation of histone H3 lysine 27.^[15]^[16] Alternatively, the dCas9 protein alone is sufficient to physically interfere with normal processes which maintain DNA methylation at the site to which it is targeted in dividing cells; this results in targeted DNA demethylation. The primary benefit of this approach is that it is free of epigenetic-modifying enzymes, which may affect epigenetic marks over large distances and act independently throughout the genome despite being tethered to a targeted dCas9 protein, often leading to widespread off-target effects.^[3]

A variant in CRISPR epigenome editing (called FIRE-Cas9) allows to reverse the changes made, in case something went wrong.^[17]^[18]

CRISPRoff is a dead Cas9 fusion protein that can be used to heritably silence the gene expression of "most genes" and allows for reversible modifications.^[19]^[20]

Commonly used effector proteins

TET1 induces demethylation of cytosine at CpG sites. This protein has been used to activate genes that are repressed by CpG methylation and to determine the role of individual CpG methylation sites.^[6] It is widely believed that targeted demethylation is typically better achieved by dCas9 alone (by targeted interference with normal DNA methylation machinery) as introduction of dCas9-TET into cells leads to widespread off-target activity of the over-expressed TET enzyme. ^[3] LSD1 induces the demethylation of H3K4me1/2, which also causes an indirect effect of deacetylation on H3K27. This effector can be used on histones in enhancer regions, which can changes the expression of neighboring genes.^[7] CIB1 is a light sensitive cryptochrome, this cryptochrome is fused to the TALE protein. A second protein contains an interaction partner (CRY2) fused with a chromatin/DNA modifier (ex. SID4X). CRY2 is able to interact with CIB1 when the cryptochrome has been activated by illumination with blue light.^[21] The interaction allows the chromatin modifier to act on the desired location. This means that the modification can be performed in an inducible and reversible manner, which reduces long-term secondary effects that would be caused by constitutive epigenetic modification.^[5]

Applications

Studying enhancer function and activity

Editing of gene enhancer regions in the genome through targeted epigenetic modification has been demonstrated by Mendenhall et al. (2013).^[7] This study utilized a TALE-LSD1 effector fusion protein in order to target enhancers of genes, to induce enhancer silencing in order to deduce enhancer activity and gene control. Targeting specific enhancers followed by locus specific RT-qPCR allows for the genes affected by the silenced enhancer to be determined. Alternatively, inducing enhancer silencing in regions upstream of genes allows for gene expression to be altered. RT-qPCR can then be utilized to study effects of this on gene expression. This allows for enhancer function and activity to be studied in detail.^[7]

Determining the function of specific methylation sites

It is important to understand the role specific methylation sites play regulating in gene expression. To study this, one research group used a TALE-TET1 fusion protein to demethylate a single CpG methylation site.^[6] Although this approach requires many controls to ensure specific binding to target loci, a properly performed study using this approach can determine the biological function of a specific CpG methylation site.^[6]

Determining the role of epigenetic modifications directly

Epigenetic editing using an inducible mechanism offers a wide array of potential use to study epigenetic effects in various states. One research group employed an optogenetic two-hybrid system which integrated the sequence specific TALE DNA-binding domain with a light-sensitive cryptochrome 2 protein (CIB1).^[5] Once expressed in the cells, the system was able to inducibly edit histone modifications and determine their function in a specific context.^[5]

Functional engineering

Targeted regulation of disease-related genes may enable novel therapies for many diseases, especially in cases where adequate gene therapies are not yet developed or are inappropriate.^[22] While transgenerational and population level consequences are not fully understood, it may become a major tool for applied functional genomics and personalized medicine.^[23] As with RNA editing, it does not involve genetic changes and their accompanying risks.^[22] One example of a potential functional use of epigenome editing was described in 2021: repressing Na_v1.7 gene expression via CRISPR-dCas9 which showed therapeutic potential in three mouse models of chronic pain.^[24]^[25]

In 2022, research assessed its usefulness in reducing tau protein levels, regulating a protein involved in Huntington's disease, targeting an inherited form of obesity, and Dravet syndrome.^[26]

Limitations

Sequence specificity is critically important in epigenome editing and must be carefully verified (this can be done using chromatin immunoprecipitation followed by Sanger sequencing to verify the targeted sequence).^[8] It is unknown if the TALE fusion may cause effects on the catalytic activity of the epigenome modifier. This could be especially important in effector proteins that require multiple subunits and complexes such as the Polycomb repressive complex.^[8] Proteins used for epigenome editing may also obstruct ligands and substrates at the target site.^[8] The TALE protein itself may even compete with transcription factors if they are targeted to the same sequence.^[8] In addition, DNA repair systems could reverse the alterations on the chromatin and prevent the desired changes from being made.^[8] Finally, enzymes fused to dCas9 typically are able to act independently of the dCas9 protein that they are fused to. When these fusions are over-expressed in cells, these enzymes tend to modify large spans of the genome in what constitutes dramatic off-target activity.^[3]^[27] It is therefore necessary for fusion constructs and targeting mechanisms to be optimized for reliable and repeatable epigenome editing.

References

^ Whitaker JW, Chen Z, Wang W (March 2015). "Predicting the human epigenome from DNA motifs". Nature Methods. 12 (3): 265–72, 7 p following 272. doi:10.1038/nmeth.3065. PMC 4344378. PMID 25240437.
^ Jones PA (May 2012). "Functions of DNA methylation: islands, start sites, gene bodies and beyond". Nature Reviews. Genetics. 13 (7): 484–92. doi:10.1038/nrg3230. PMID 22641018. S2CID 3346812.
^ ^a ^b ^c ^d Sapozhnikov, Daniel M.; Szyf, Moshe (29 September 2021). "Unraveling the functional role of DNA demethylation at specific promoters by targeted steric blockage of DNA methyltransferase with CRISPR/dCas9". Nature Communications. 12 (1): 5711. Bibcode:2021NatCo..12.5711S. doi:10.1038/s41467-021-25991-9. PMC 8481236. PMID 34588447.
^ Gaj T, Gersbach CA, Barbas CF (July 2013). "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering". Trends in Biotechnology. 31 (7): 397–405. doi:10.1016/j.tibtech.2013.04.004. PMC 3694601. PMID 23664777.
^ ^a ^b ^c ^d ^e Konermann S, Brigham MD, Trevino A, Hsu PD, Heidenreich M, Cong L, et al. (August 2013). "Optical control of mammalian endogenous transcription and epigenetic states". Nature. 500 (7463): 472–476. Bibcode:2013Natur.500..472K. doi:10.1038/nature12466. PMC 3856241. PMID 23877069.
^ ^a ^b ^c ^d ^e ^f Maeder ML, Angstman JF, Richardson ME, Linder SJ, Cascio VM, Tsai SQ, et al. (December 2013). "Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins". Nature Biotechnology. 31 (12): 1137–42. doi:10.1038/nbt.2726. PMC 3858462. PMID 24108092.
^ ^a ^b ^c ^d ^e Mendenhall EM, Williamson KE, Reyon D, Zou JY, Ram O, Joung JK, Bernstein BE (December 2013). "Locus-specific editing of histone modifications at endogenous enhancers". Nature Biotechnology. 31 (12): 1133–6. doi:10.1038/nbt.2701. PMC 3858395. PMID 24013198.
^ ^a ^b ^c ^d ^e ^f Voigt P, Reinberg D (December 2013). "Epigenome editing". Nature Biotechnology. 31 (12): 1097–9. doi:10.1038/nbt.2756. PMID 24316647. S2CID 28191072.
^ Chen H, Kazemier HG, de Groote ML, Ruiters MH, Xu GL, Rots MG (February 2014). "Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter". Nucleic Acids Research. 42 (3): 1563–74. doi:10.1093/nar/gkt1019. PMC 3919596. PMID 24194590.
^ Kungulovski G, Nunna S, Thomas M, Zanger UM, Reinhardt R, Jeltsch A (2015-03-18). "Targeted epigenome editing of an endogenous locus with chromatin modifiers is not stably maintained". Epigenetics & Chromatin. 8 (1): 12. doi:10.1186/s13072-015-0002-z. PMC 4404288. PMID 25901185.
^ Bustos FJ, Ampuero E, Jury N, Aguilar R, Falahi F, Toledo J, et al. (December 2017). "Epigenetic editing of the Dlg4/PSD95 gene improves cognition in aged and Alzheimer's disease mice". Brain. 140 (12): 3252–3268. doi:10.1093/brain/awx272. PMC 5841035. PMID 29155979.
^ Biolabs, New England. "CRISPR/Cas9 and Targeted Genome Editing: A New Era in Molecular Biology | NEB". www.neb.com. Retrieved 2016-06-07.
^ "Addgene: CRISPR/Cas9 Guide". www.addgene.org. Retrieved 2016-06-07.
^ McDonald JI, Celik H, Rois LE, Fishberger G, Fowler T, Rees R, et al. (June 2016). "Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation". Biology Open. 5 (6): 866–74. doi:10.1242/bio.019067. PMC 4920199. PMID 27170255.
^ Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, Gersbach CA (May 2015). "Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers". Nature Biotechnology. 33 (5): 510–7. doi:10.1038/nbt.3199. PMC 4430400. PMID 25849900.
^ Cervantes-Gracia K, Gramalla-Schmitz A, Weischedel J, Chahwan R (2021). "APOBECs orchestrate genomic and epigenomic editing across health and disease". Trends Genet. 37 (11): 1028–1043. doi:10.1016/j.tig.2021.07.003. PMID 34353635. S2CID 236934922.
^ Braun, Simon M. G.; Kirkland, Jacob G.; Chory, Emma J.; Husmann, Dylan; Calarco, Joseph P.; Crabtree, Gerald R. (2017). "Rapid and reversible epigenome editing by endogenous chromatin regulators". Nature Communications. 8 (1): 560. Bibcode:2017NatCo...8..560B. doi:10.1038/s41467-017-00644-y. PMC 5601922. PMID 28916764.
^ Liu XS, Wu H, Krzisch M, Wu X, Graef J, Muffat J, et al. (February 2018). "Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene". Cell. 172 (5): 979–992.e6. doi:10.1016/j.cell.2018.01.012. PMC 6375087. PMID 29456084.
^ "New, reversible CRISPR method can control gene expression while leaving underlying DNA sequence unchanged". phys.org. Retrieved 10 May 2021.
^ Nuñez, James K.; Chen, Jin; Pommier, Greg C.; Cogan, J. Zachery; Replogle, Joseph M.; Adriaens, Carmen; Ramadoss, Gokul N.; Shi, Quanming; Hung, King L.; Samelson, Avi J.; Pogson, Angela N.; Kim, James Y. S.; Chung, Amanda; Leonetti, Manuel D.; Chang, Howard Y.; Kampmann, Martin; Bernstein, Bradley E.; Hovestadt, Volker; Gilbert, Luke A.; Weissman, Jonathan S. (29 April 2021). "Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing". Cell. 184 (9): 2503–2519.e17. doi:10.1016/j.cell.2021.03.025. ISSN 0092-8674. PMC 8376083. PMID 33838111.
^ Liu H, Yu X, Li K, Klejnot J, Yang H, Lisiero D, Lin C (December 2008). "Photoexcited CRY2 interacts with CIB1 to regulate transcription and floral initiation in Arabidopsis". Science. 322 (5907): 1535–9. Bibcode:2008Sci...322.1535L. doi:10.1126/science.1163927. PMID 18988809. S2CID 3003167.
^ ^a ^b Kungulovski, Goran; Jeltsch, Albert (1 February 2016). "Epigenome Editing: State of the Art, Concepts, and Perspectives". Trends in Genetics. 32 (2): 101–113. doi:10.1016/j.tig.2015.12.001. ISSN 0168-9525. PMID 26732754. Retrieved 30 April 2021.
^ Laufer, Benjamin I.; Singh, Shiva M. (17 September 2015). "Strategies for precision modulation of gene expression by epigenome editing: an overview". Epigenetics & Chromatin. 8 (1): 34. doi:10.1186/s13072-015-0023-7. ISSN 1756-8935. PMC 4574080. PMID 26388942.
^ "Unique CRISPR gene therapy offers opioid-free chronic pain treatment". New Atlas. 11 March 2021. Retrieved 18 April 2021.
^ Moreno, Ana M.; Alemán, Fernando; Catroli, Glaucilene F.; Hunt, Matthew; Hu, Michael; Dailamy, Amir; Pla, Andrew; Woller, Sarah A.; Palmer, Nathan; Parekh, Udit; McDonald, Daniella; Roberts, Amanda J.; Goodwill, Vanessa; Dryden, Ian; Hevner, Robert F.; Delay, Lauriane; Santos, Gilson Gonçalves dos; Yaksh, Tony L.; Mali, Prashant (10 March 2021). "Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice". Science Translational Medicine. 13 (584): eaay9056. doi:10.1126/scitranslmed.aay9056. ISSN 1946-6234. PMC 8830379. PMID 33692134. S2CID 232170826.
^ Kaiser, Jocelyn (1 June 2022). "Better than CRISPR? Another way to fix gene problems may be safer and more versatile". www.science.org. Retrieved 2022-08-21.
^ Galonska, C; Charlton, J; Mattei, AL; Donaghey, J; Clement, K; Gu, H; Mohammad, AW; Stamenova, EK; Cacchiarelli, D; Klages, S; Timmermann, B; Cantz, T; Schöler, HR; Gnirke, A; Ziller, MJ; Meissner, A (9 February 2018). "Genome-wide tracking of dCas9-methyltransferase footprints". Nature Communications. 9 (1): 597. Bibcode:2018NatCo...9..597G. doi:10.1038/s41467-017-02708-5. PMC 5807365. PMID 29426832.